<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582320</url>
  </required_header>
  <id_info>
    <org_study_id>LLC1415</org_study_id>
    <nct_id>NCT02582320</nct_id>
  </id_info>
  <brief_title>Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program</brief_title>
  <official_title>A Retrospective Study to Evaluate the Clinical-Biologic Characteristics and Outcome of Patients Treated in Italy According to the Ibrutinib-Named Patient Program for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a retrospective observational study aimed at describing the characteristics and
      outcome of CLL patients included in the NPP in Italy in a period of time ranging from the
      start of the NPP until November, 30th 2014. A longitudinal survey will be carried out by
      collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be
      observed for at least 12 months from the treatment start.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. The disease is
      characterized by the progressive accumulation of phenotypically mature malignant B
      lymphocytes, primarily in the peripheral blood, bone marrow, and lymph nodes. Over the last
      10-15 years several biological prognostic markers have been identified, starting from the
      immunoglobulin gene mutational analysis to CD38, ZAP70, CD49d expression, and many others.
      The very recent discovery of several new genes that carry point mutations in CLL, including
      NOTCH1, SF3B1 and BIRC3, has added more markers that seem to correlate with resistance to
      treatment and with transformation into Richter syndrome. A large number of chemoimmunotherapy
      regimens are currently considered for the treatment of CLL patients.

      NPP program The Named Patient Program (NPP) is a program intended to provide early access to
      ibrutinib in Italy. This program is specifically for patients who have relapsed or refractory
      chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma.

      Rationale In patients with CLL Ibrutinib, given as single agent has shown marked activity and
      a good safety profile. Data from patients treated with ibrutinib outside a controlled
      clinical trial within a National Patient Program (NPP) could give additional information
      about the clinical use, treatment duration, efficacy, and toxicity of ibrutinib given to CLL
      patients in a real life context.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who progress</measure>
    <time_frame>At 12 months from the start of Ibrutinib</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who respond to treatment</measure>
    <time_frame>At 12 months from enrolment</time_frame>
    <description>CR,PR, L-PR according to the IWCLL 2008 criteria with modification for treatment-related lymphocytosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment duration</measure>
    <time_frame>At 12 months from enrolment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment in terms of number of days needed</measure>
    <time_frame>At 12 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients surviving</measure>
    <time_frame>At 12 months from treatment start</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who reach normal values in the immunoglobulin levels</measure>
    <time_frame>At 3, 6 and 12 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with toxic events</measure>
    <time_frame>At 12 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who develop Richter's syndrome and secondary malignancies</measure>
    <time_frame>At 12 months from treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who require added assistance</measure>
    <time_frame>At 12 months from treatment start</time_frame>
    <description>For example: hospitalization, emergency visits, blood product transfusions and use of hematopoietic growth factors, antibiotics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who fail to treatment.</measure>
    <time_frame>At 12 months from treatment start</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">215</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Study patients</arm_group_label>
    <description>Patients with Relapsed or refractory CLL or 17p deleted CLL fulfilling the eligibility criteria required by the Named Patient Program (NPP) who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.</description>
    <arm_group_label>Study patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with R/R CLL or 17p deleted CLL fulfilling the eligibility criteria required by
        the NPP who received at least 1 dose of Ibrutinib 420 mg daily before November, 30th 2014
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        NPP Inclusion Criteria:

          1. Patients ≥18 years of age.

          2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.

          3. A minimum of one prior line of systemic chemotherapy, chemo-immunotherapy, or an
             alemtuzumab-based regimen, consisting of at least two cycles of therapy.

          4. Relapsed or refractory CLL with one or more of the following criteria:

               -  Presence of deletion of the short-arm of chromosome 17 (ie 17p deletion).

               -  Relapsed: Failed two or more previous treatments, at least one with a purine
                  analogue such as fludarabine.

               -  Relapsed: Progression-free interval of less than 24 months from completing
                  treatment with a nucleoside analogue, or bendamustine-containing regimen in
                  combination with an anti-CD20 monoclonal antibody such as rituximab.

               -  Refractory: Failure to respond to a prior chemotherapy-based treatment, stable
                  disease, or disease progression while on treatment.

          5. Patient has active CLL requiring treatment as defined by the IWCLL 2008 criteria. A
             minimum of one of the following criteria is required:

               -  Evidence of progressive marrow failure, as manifested by the development of, or
                  worsening of, anemia or thrombocytopenia.

               -  Massive (at least 6 cm below the left costal margin), progressive, or symptomatic
                  splenomegaly.

                  c. Massive nodes (at least 10 cm in longest diameter), progressive, or
                  symptomatic lymphadenopathy.

               -  Progressive lymphocytosis with an increase of more than 50% over a 2-month period
                  or a lymphocyte doubling time of less than 6 months (which may be extrapolated).
                  For patients with initial blood lymphocyte counts of less than 30 x 109/L
                  (30,000/mL), lymphocyte doubling time should not be used as a single parameter to
                  define indication for treatment. Factors contributing to lymphocytosis or
                  lymphadenopathy other than CLL (e.g., infections) should be excluded.

               -  Constitutional symptoms, defined as 1 or more of the following disease-related
                  symptoms or signs:

                  i. Unintentional weight loss &gt;10% within the previous 6 months prior to
                  screening.

             ii. Significant fatigue (inability to work or perform usual activities). iii. Fever
             higher than 38.0°C for 2 or more weeks without evidence of infection.

             iv. Night sweats for more than 1 month without evidence of infection.

          6. Haematology values within the following parameters:

               -  Absolute neutrophil count (ANC) of ≥0.75 x109/L independent of growth factor
                  support.

               -  Platelet count of ≥30 x109/L independent of platelet support.

          7. Biochemical values within the following limits:

               -  Serum creatinine ≤2 times the upper limit of normal (ULN) or estimated glomerular
                  filtration rate (GFR [Crockcoft-Gault]) ≥30 mL/minute.

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 times
                  ULN.

               -  Total bilirubin ≤1.5 times ULN (unless the bilirubin rise is due to Gilbert's
                  syndrome or of non-hepatic origin) for whom the upper limit of serum bilirubin is
                  3 mg/dl.

          8. No problems to swallowing regularly capsules.

          9. Agreed to practice a highly effective method of birth control during and after
             participation in the NPP if they are of childbearing potential and sexually active.

         10. Signed informed consent document (if feasible) indicating that they understand the
             purpose of the study, they agree to give complete access to their medical records.

        NPP Exclusion criteria

          1. Previous treatment with ibrutinib or participation to an ibrutinib clinical trial
             (ibrutinib or comparator arm).

          2. Eligible to participate in a currently recruiting ibrutinib clinical trial.

          3. Previously received ibrutinib as part of a clinical trial.

          4. Previously received a Bruton's tyrosine kinase (BTK) inhibitor other than ibrutinib.

          5. Currently enrolled in an interventional clinical trial.

          6. Currently receiving chemotherapy, anticancer immunotherapy, or experimental therapy.

          7. Currently recovering from acute toxicities of prior treatment for CLL.

          8. Received stem cell transplantation within the past 6 months.

          9. Evidence of graft-versus-host disease and/or requires immunosuppressant therapy.

         10. Major surgery within the past 4 weeks or a major wound that has not fully healed.

         11. History of human immunodeficiency virus (HIV) or active infection with Hepatitis C or
             B.

         12. Ongoing uncontrolled active systemic infection.

         13. Uncontrolled autoimmune haemolytic anemia (AIHA).

         14. Uncontrolled idiopathic thrombocytopenic purpura (ITP).

         15. Central nervous system leukemia/lymphoma or Richter's transformation.

         16. Diagnosed or treated for another malignancy, other than CLL, except for:

               -  Malignancy treated with curative intent and with no known active disease present
                  for ≥3 years prior to entering this named patient program and considered to be at
                  low risk for recurrence.

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease.

               -  Adequately treated cervical carcinoma in situ without evidence of disease.

         17. Stroke within the past 6 months.

         18. Intracranial haemorrhage within the past 6 months.

         19. Requires anticoagulation with warfarin or equivalent vitamin K antagonist (e.g.
             phenprocoumon).

         20. Requires treatment with a strong CYP3A inhibitor.

         21. Clinically significant cardiovascular disease such as:

               -  Uncontrolled or symptomatic arrhythmias.

               -  Congestive heart failure.

               -  Myocardial infarction within the past 6 months.

               -  Class 3 or 4 cardiac disease as defined by the New York Heart Association
                  Functional Classification.

         22. Patient has any life-threatening illness, medical condition, clinically significant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roberto Foà</last_name>
    <role>Study Chair</role>
    <affiliation>Policlinico Umberto I, Hematology Department.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Terapia Cellulare - Ospedale &quot;C. e G. Mazzoni&quot; di Ascoli Piceno</name>
      <address>
        <city>Ascoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piero Galieni</last_name>
    </contact>
    <investigator>
      <last_name>Piero Galieni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C di Ematologia P.O. &quot;S.Giuseppe Moscati&quot; - 2° piano</name>
      <address>
        <city>Aversa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Caparrotti</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Caparrotti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Esposito</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giorgina Specchia</last_name>
    </contact>
    <investigator>
      <last_name>Giorgina Specchia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giulio Giordano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;Lorenzo e A. Seragnoli&quot; - Università degli Studi di Bologna - Policlinico S. Orsola - Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierluigi Zinzani</last_name>
    </contact>
    <investigator>
      <last_name>Pierluigi Zinzani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spedali Civili - Brescia - Azienda Ospedaliera - U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Motta</last_name>
    </contact>
    <investigator>
      <last_name>Marina Motta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia Ospedale A. Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Melpignano</last_name>
    </contact>
    <investigator>
      <last_name>Angela Melpignano</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>G. Quintana</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL N.8 - Ospedale &quot;A. Businco&quot; - Struttura Complessa di Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Murru</last_name>
    </contact>
    <investigator>
      <last_name>Roberta Murru</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefania Massidda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Dipartimentale - Centro per le malattie del sangue - Ospedale Civile - S.Giacomo</name>
      <address>
        <city>Castelfranco Veneto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Tagariello</last_name>
    </contact>
    <investigator>
      <last_name>Giuseppe Tagariello</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Sartori</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Pugliese Ciaccio - Presidio Ospedaliero A.Pugliese - Unità Operativa di Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Molica</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Molica</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosanna Mirabelli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Medicina Interna - ASUR Marche 8 - Ospedale Civile</name>
      <address>
        <city>Civitanova Marche</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riccardo Centurioni</last_name>
    </contact>
    <investigator>
      <last_name>Riccardo Centurioni</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milena Mirabile</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Arcispedale Sant'Anna Dipartimento di Scienze Mediche Sezione di Ematologia e Fisiopatologia dell'Emostasi</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Cuneo</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Cueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gian Matteo Rigolin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità di Ricerca e di Malattie del sangue - Ematologia San Luca Vecchio Pad. 16 - 1° Piano</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alberto Bosi</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Bosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Riccardo Boncompagni</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS_AOU San Martino-IST.Clinica Ematologica</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Gobbi</last_name>
    </contact>
    <investigator>
      <last_name>Marco Gobbi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Le/1 P.O. Vito Fazzi - U.O. di Ematologia ed UTIE</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Di Renzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Raffaela Fadda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC Oncoematologia- Padiglione Marcora 2° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agostino Cortelezzi</last_name>
    </contact>
    <investigator>
      <last_name>Gianluigi Reda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Agostino Cortelezzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Niguarda &quot; Ca Granda&quot; - SC Ematologia Blocco SUD, Ponti Est, Scala E, 4° piano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Tedeschi</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Tedeschi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maddalena Mazzucchelli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia e Trapianto di MIdollo - Ist.Scientifico Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Ghia</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Ghia</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lydia Scarfò</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Trapianto di Midollo Ist. Nazionale Tumori</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Farina</last_name>
    </contact>
    <investigator>
      <last_name>Lucia Farina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia - AOU Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Marasca</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Marasca</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanna Leonardi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gennaro - ASL Napoli 1</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucia Mastrullo</last_name>
    </contact>
    <investigator>
      <last_name>Lucia Mastrullo</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Rosaria Villa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C.D.U. Ematologia - DIMECS e Dipartimento Oncologico - Università del Piemonte Orientale Amedeo Avogadro</name>
      <address>
        <city>Novara di Sicilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianluca Gaidano</last_name>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Padova - Ematologia ed Immunologia Clinica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Livio Trentin</last_name>
    </contact>
    <investigator>
      <last_name>Livio Trentin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncoematologia di Nocera Inferiore-plesso ospedaliero &quot;A. Tortora&quot; di Pagani del DEA Nocera-Pagani</name>
      <address>
        <city>Pagani</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Castello Califani</last_name>
    </contact>
    <investigator>
      <last_name>Maria Lucia Barone</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Castello Califano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cattedra di Ematologia CTMO Università degli Studi di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Re</last_name>
    </contact>
    <investigator>
      <last_name>Francesca Re</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Filomena Russo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. Ematologia - Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ester Orlandi</last_name>
    </contact>
    <investigator>
      <last_name>Ester Orlandi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianna Rossi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia ed Immunologia Clinica - Ospedale S.Maria della Misericordia</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Falzetti</last_name>
    </contact>
    <investigator>
      <last_name>Franca Falzetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Ematologia Clinica - Azienda USL di Pescara</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Angrilli</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Angrilli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erica Finolezzi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Ematologia e Centro Trapianti - Dipartimento di Oncologia ed Ematologia - AUSL Ospedale G. da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniele Vallisa</last_name>
    </contact>
    <investigator>
      <last_name>Daniele Vallisa</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annalisa Arcari</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia - Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Pizzuti</last_name>
    </contact>
    <investigator>
      <last_name>Michele Pizzuti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Immacolata Attolito</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Oncologico - Ospedale S.Maria delle Croci</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Tani</last_name>
    </contact>
    <investigator>
      <last_name>Monica Tani</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giulia Daghia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento Emato-Oncologia A.O.&quot;Bianchi-Melacrino-Morelli&quot;</name>
      <address>
        <city>Reggio Calabria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iolanda Donatella</last_name>
    </contact>
    <investigator>
      <last_name>Iolanda Donatella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Ematologia - Arcispedale S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiorella Ilariucci</last_name>
    </contact>
    <investigator>
      <last_name>Angelo Fama</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fiorella Ilariucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi&quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Lia Molinari</last_name>
    </contact>
    <investigator>
      <last_name>Anna Lia Molinari</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrizia Tosi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Terapia Cellulare - Ospedale &quot;C. e G. Mazzoni&quot; di Ascoli Piceno</name>
      <address>
        <city>Rionero in Vulture</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni D'Arena</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni D'Arena</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oreste Villani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Mengarelli</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Mengarelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Palombi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia - Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Del Poeta</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Del Poeta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.S.A. Ematologia ASL RMA Presidio Nuovo Regina Margherita</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Andriani</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Andriani</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefano Felici</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Laurenti</last_name>
    </contact>
    <investigator>
      <last_name>Luca Laurenti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Idanna Innocenti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli Studi &quot;Sapienza&quot; - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Foà</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Foà</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Mauro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I, Hematology Department - Sapienza</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Foà</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sezione di Ematologia Cancer Center Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Carlo Stella</last_name>
    </contact>
    <investigator>
      <last_name>Carmelo Carlo Stella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>S. G. Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla</last_name>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosaria Potito</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Ematologia e Trapianti - A.O. Senese - Policlinico &quot; Le Scotte&quot;</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Gozzetti</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Gozzetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Veronica Candi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Santa Maria - Terni S.C Oncoematologia</name>
      <address>
        <city>Terni</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maria Liberati</last_name>
    </contact>
    <investigator>
      <last_name>Anna Maria Liberati</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilaria Angeletti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia ed Ematologia S.C. Ematologia 2 A.O. Città della Salute e della Scienza di Torino San Giovanni Battista</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorella Orsucci</last_name>
    </contact>
    <investigator>
      <last_name>Lorella Orsucci</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia dell' Università degli Studi di Torino - &quot;Città della Salute e della Scienza di Torino&quot;</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Coscia</last_name>
    </contact>
    <investigator>
      <last_name>Marta Coscia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS N.6 Osp. S. Bortolo</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Visco</last_name>
    </contact>
    <investigator>
      <last_name>Carlo Visco</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2015</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

